Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line

Exclusion Criteria

• •1. Clinical suspicion or documentation of histological transformation.
• •2. Patients with hypersensitivity to rituximab.
• •3. Prior autologous or allogeneic transplant.
• •4. CNS infiltration by LF (primary CNS lymphoma or lymphomatous meningitis).
• •5. Past or active Hepatitis B (at least one of the following markers HBsAg, HBe Ag, anti-HBc, HBV DNA).
• •6. HCV infection. HIV infection or other conditions of severe immunosuppression.
• •7. Previous neoplasms except non-melanoma skin cancer of the cervix or adequately treated.
• •8. Congestive heart failure\> NYHA grade 1.
• •9. Impaired renal function (creatinine\> 1.5 x Upper Limit of Normal, ULN) or creatinine clearance \<50 ml / h, not related to lymphoma.
• •10. Impaired liver function (bilirubin, AST / ALT or GGT\> 2 x ULN) were not related to lymphoma.
• •11. Women who are nursing or pregnant.
• •12. Patients with heart disease, pulmonary, neurological, psychiatric or severe metabolic and not secondary to lymphoma.
• •13. Severe acute or chronic infection in activity.
• •14. Any other concurrent medical or psychological comorbidity that might interfere with participation in this study.